Program: Oral and Poster Abstracts
Session: 701. Experimental Transplantation: Basic Biology, Engraftment and Disease Activity: Poster II
Results: Here, we describe a hitherto unrecognized regenerative function for the RIG-I/MAVS/IFN-I pathway through direct effects on epithelial regeneration. Mice deficient in the RIG-I adaptor MAVS were more sensitive to intestinal barrier damage after total body irradiation (TBI) and, like RIG-I deficient mice, developed worse graft-versus-host disease (GVHD) in a preclinical model for allogeneic hematopoietic stem cell transplantation (allo-HSCT). This phenotype was not associated with changes in the intestinal microbiota, but with a defect in epithelial regeneration. Moreover, in contrast to previous reports in steady-state conditions and after viral challenge, we found that interferon-α/β receptor (IFNAR) signaling in non-hematopoietic epithelial cells was crucial for tissue regeneration after acute damage. Importantly, we could demonstrate that this pathway could be therapeutically targeted with RIG-I agonists, which promoted barrier integrity and prevented GVHD. Mechanistically, Type I IFNs (either RIG-I-induced or recombinant) could promote intestinal stem cell (ISC) growth in crypt organoid cultures, suggesting that stimulation of the ISC compartment led to epithelial regeneration.
Conclusion: Our findings suggest that activation of RIG-I and IFN-I can promote regeneration of intestinal epithelial cells and thus offers an innovative therapeutic strategy for the management of acute intestinal injury.
Disclosures: van den Brink: Merck: Honoraria ; Boehringer Ingelheim: Consultancy , Other: Advisory board attendee ; Regeneron: Honoraria ; Novartis: Consultancy , Membership on an entity’s Board of Directors or advisory committees ; Tobira Therapeutics: Other: Advisory board attendee .
See more of: Experimental Transplantation: Basic Biology, Engraftment and Disease Activity
See more of: Oral and Poster Abstracts
*signifies non-member of ASH